A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab

Theranostics - Canada
doi 10.7150/thno.12040
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ivyspring International Publisher

Related search

Efficacy of Rituximab (Anti-Cd20) for Refractory Systemic Lupus Erythematosus Involving the Central Nervous System

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2006English

Two Structurally Different Rituximab-Specific CD20 Mimotope Peptides Reveal That Rituximab Recognizes Two Different CD20-Associated Epitopes

Journal of Immunology
AllergyImmunology
2008English

B Cell Therapy for Rheumatoid Arthritis: The Rituximab (Anti-Cd20) Experience

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2003English

Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates

Molecules
Organic ChemistryMolecular MedicineAnalytical ChemistryTheoretical ChemistryPharmaceutical ScienceMedicineDrug DiscoveryChemistryPhysical
2015English

A Step Towards a New Targeted Nanotherapy for Pancreatic Cancer

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2008English

Regulation of CD20 in Rituximab-Resistant Cell Lines and B-Cell Non-Hodgkin Lymphoma

Clinical Cancer Research
Cancer ResearchOncology
2012English

Characterization of Novel Murine Anti-Cd20 Monoclonal Antibodies and Their Comparison to 2B8 and C2B8 (Rituximab)

International Journal of Oncology
Cancer ResearchOncology
2007English

Rituximab in CD20 Positive Multiple Myeloma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2007English

Phase I Study of Chimeric Anti-Cd20 Monoclonal Antibody in Chinese Patients With CD20-positive Non-Hodgkin’s Lymphoma

Chinese Journal of Cancer Research
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy